# Singe Dose, First in Human Study of PF- 06946860 in Healthy Adult Subjects

> **NCT03599063** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 63 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** PF-06946860
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03599063
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-30
- **Primary completion:** 2019-09-18
- **Final completion:** 2019-09-18
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2019-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03599063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03599063, "Singe Dose, First in Human Study of PF- 06946860 in Healthy Adult Subjects". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03599063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*